Emmie Banks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emmie Banks has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Adam P. Mecca
Department of Psychiatry and Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, CT, USA
2 shared publications - Mika Naganawa
Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA
2 shared publications - Nabeel Nabulsi
Department of Radiology and Biomedical Engineering, Yale University School of Medicine, New Haven, CT, USA
2 shared publications - Richard E. Carson
Yale University
2 shared publications Wenzhen Zhao
Alzheimer’s Disease Research Unit, Yale University School of Medicine, One Church Street, 8th Floor, New Haven, CT, 06510, USA
2 shared publications- Albert Tzongyang Higgins-Chen
Department of Psychiatry, Yale University School of Medicine, New Haven, USA
1 shared publication
Latest Publications
- Open Access
Entorhinal cortex vulnerability to human APP expression promotes hyperexcitability and tau pathology
Preventative treatment for Alzheimer’s Disease is of dire importance, and yet, cellular mechanisms underlying early regional vulnerability in Alzheimer’s Disease remain unknown. In human patients with Alzheimer’s Disease, one of the earliest observed pathophysiological correlates to cognitive decline is hyperexcitability. In mouse models, early hyperexcitability has been shown in the entorhinal cortex, the first cortical region impacted by Alzheimer’s Disease. The origin of hyperexcitability in early-stage disease and why it preferentially emerges in specific regions is unclear. Using cortical-region and cell-type-specific proteomics coupled with ex vivo and in vivo electrophysiology, we uncovered differential susceptibility to human-specific amyloid precursor protein (hAPP) in a model of sporadic Alzheimer’s. Unexpectedly, our findings reveal that early entorhinal hyperexcitability may result from intrinsic vulnerability of parvalbumin (PV) interneurons, rather than the suspected layer II excitatory neurons. This vulnerability of entorhinal PV interneurons is specific to hAPP, as it could not be recapitulated with increased murine APP expression. However, partial replication of the findings could be seen after introduction of a murine APP chimera containing a humanized amyloid-beta sequence. Surprisingly, neurons in the Somatosensory Cortex showed no such vulnerability to adult-onset hAPP expression. hAPP-induced hyperexcitability in entorhinal cortex could be ameliorated by enhancing PV interneuron excitability in vivo. Co-expression of human Tau with hAPP decreased circuit hyperexcitability, but at the expense of increased pathological tau species. This study suggests early disease interventions targeting non-excitatory cell types may protect regions with early vulnerability to pathological symptoms of Alzheimer’s Disease and downstream cognitive decline.
Open AccessEntorhinal cortex vulnerability to human APP expression promotes hyperexcitability and tau pathology
Preventative treatment for Alzheimer’s Disease is of dire importance, and yet, cellular mechanisms underlying early regional vulnerability in Alzheimer’s Disease remain unknown. In human patients with Alzheimer’s Disease, one of the earliest observed pathophysiological correlates to cognitive decline is hyperexcitability. In mouse models, early hyperexcitability has been shown in the entorhinal cortex, the first cortical region impacted by Alzheimer’s Disease. The origin of hyperexcitability in early-stage disease and why it preferentially emerges in specific regions is unclear. Using cortical-region and cell-type-specific proteomics coupled with ex vivo and in vivo electrophysiology, we uncovered differential susceptibility to human-specific amyloid precursor protein (hAPP) in a model of sporadic Alzheimer’s. Unexpectedly, our findings reveal that early entorhinal hyperexcitability may result from intrinsic vulnerability of parvalbumin (PV) interneurons, rather than the suspected layer II excitatory neurons. This vulnerability of entorhinal PV interneurons is specific to hAPP, as it could not be recapitulated with increased murine APP expression. However, partial replication of the findings could be seen after introduction of a murine APP chimera containing a humanized amyloid-beta sequence. Surprisingly, neurons in the Somatosensory Cortex showed no such vulnerability to adult-onset hAPP expression. hAPP-induced hyperexcitability in entorhinal cortex could be ameliorated by enhancing PV interneuron excitability in vivo. Co-expression of human Tau with hAPP decreased circuit hyperexcitability, but at the expense of increased pathological tau species. This study suggests early disease interventions targeting non-excitatory cell types may protect regions with early vulnerability to pathological symptoms of Alzheimer’s Disease and downstream cognitive decline.
- 1 December 2022
- Published by American Psychological Association (APA) in Journal of Personality and Social Psychology
- Vol. 123 (6) , 1199-1222
The affective harm account (AHA) of moral judgment: Reconciling cognition and affect, dyadic morality and disgust, harm and purity.
Moral psychology has long debated whether moral judgment is rooted in harm versus affect. We reconcile this debate with the affective harm account (AHA) of moral judgment. The AHA understands harm as an intuitive perception (i.e., perceived harm), and divides "affect" into two: embodied visceral arousal (i.e., gut feelings) and stimulus-directed affective appraisals (e.g., ratings of disgustingness). The AHA was tested in a randomized, double-blind pharmacological experiment with healthy young adults judging the immorality, harmfulness, and disgustingness of everyday moral scenarios (e.g., lying) and unusual purity scenarios (e.g., sex with a corpse) after receiving either a placebo or the β-blocker propranolol (a drug that dampens visceral arousal). Results confirmed the three key hypotheses of the AHA. First, perceived harm and affective appraisals are neither competing nor independent but intertwined. Second, although both perceived harm and affective appraisals predict moral judgment, perceived harm is consistently relevant across all scenarios (in line with the theory of dyadic morality), whereas affective appraisals are especially relevant in unusual purity scenarios (in line with affect-as-information theory). Third, the "gut feelings" of visceral arousal are not as important to morality as often believed. Dampening visceral arousal (via propranolol) did not directly impact moral judgment, but instead changed the relative contribution of affective appraisals to moral judgment-and only in unusual purity scenarios. By embracing a constructionist view of the mind that blurs traditional dichotomies, the AHA reconciles historic harm-centric and current affect-centric theories, parsimoniously explaining judgment differences across various moral scenarios without requiring any "moral foundations." (PsycInfo Database Record (c) 2022 APA, all rights reserved).
- 1 December 2022
- Published by American Psychological Association (APA) in Journal of Personality and Social Psychology
- Vol. 123 (6) , 1199-1222
The affective harm account (AHA) of moral judgment: Reconciling cognition and affect, dyadic morality and disgust, harm and purity.
Moral psychology has long debated whether moral judgment is rooted in harm versus affect. We reconcile this debate with the affective harm account (AHA) of moral judgment. The AHA understands harm as an intuitive perception (i.e., perceived harm), and divides "affect" into two: embodied visceral arousal (i.e., gut feelings) and stimulus-directed affective appraisals (e.g., ratings of disgustingness). The AHA was tested in a randomized, double-blind pharmacological experiment with healthy young adults judging the immorality, harmfulness, and disgustingness of everyday moral scenarios (e.g., lying) and unusual purity scenarios (e.g., sex with a corpse) after receiving either a placebo or the β-blocker propranolol (a drug that dampens visceral arousal). Results confirmed the three key hypotheses of the AHA. First, perceived harm and affective appraisals are neither competing nor independent but intertwined. Second, although both perceived harm and affective appraisals predict moral judgment, perceived harm is consistently relevant across all scenarios (in line with the theory of dyadic morality), whereas affective appraisals are especially relevant in unusual purity scenarios (in line with affect-as-information theory). Third, the "gut feelings" of visceral arousal are not as important to morality as often believed. Dampening visceral arousal (via propranolol) did not directly impact moral judgment, but instead changed the relative contribution of affective appraisals to moral judgment-and only in unusual purity scenarios. By embracing a constructionist view of the mind that blurs traditional dichotomies, the AHA reconciles historic harm-centric and current affect-centric theories, parsimoniously explaining judgment differences across various moral scenarios without requiring any "moral foundations." (PsycInfo Database Record (c) 2022 APA, all rights reserved).
- Open Access
- 20 November 2021
- Published by Elsevier in Neurobiology of Aging
- Vol. 111, 44-53
Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease
- 20 November 2021
- Published by Elsevier in Neurobiology of Aging
- Vol. 111, 44-53
Open AccessAssociation of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease
- 1 April 2021
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 29 (4) , S47-S48
Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease
- 1 April 2021
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 29 (4) , S47-S48
Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease